Understanding ENTA’s phase-3 program: The fact that no one answered the simple quiz in #msg-92032877 suggests to me that readers of this board who follow the HCV arena didn’t actually read the phase-3 trial listing in #msg-92025068, but rather bookmarked it for future reference.
I would respectfully recommend that anyone who wants to get comfortable with investing in ENTA should know what each of the nine listed trials in #msg-92025068 is attempting to show and how it fits into ABBV/ENTA’s overall HCV program. It’s not hard!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”